Alzinova: Full analysis confirm positive phase Ib results - Redeye

Redeye leaves a comment following Alzinova’s announcement of a completed primary analysis of the phase Ib study with its vaccine candidate ALZ-101. We are encouraged to learn that the analysis confirms the positive topline results, suggesting that ALZ-101 is well-tolerated and safe, and elicits a high immune response in patients.

Länk till analysen i sin helhet: https://www.redeye.se/research/973041/alzinova-full-analysis-confirm-positive-phase-ib-results?utm_source=finwire&utm_medium=RSS